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Abstract. The c-Jun N-terminal kinases (JNK) are members of the 
MAPK family and can be activated by different stimuli such as 
cellular stress, heat shock and ultra-violet irradiation. JNKs have 
different physiological functions and they have been linked to 
apoptosis in different cell types. Therefore, the JNK signalling 
pathway is an important target to prevent cell death. In the present 
chapter, the role of JNKs in neurodegenerative diseases will be 
discussed, as well as the pharmacological compounds that inhibit 
this signalling pathway as therapeutic intervention to prevent 
neuronal death. 
 
Introduction 
 
 Mitogen-activated protein kinases (MAPKs) are part of a signalling 
cascade    that allows the cell to respond to  exogenous and endogenous stimuli.    
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MAPK translates and integrates signals into complex cytoplasmic and 
nuclear processes and it is involved in organized cellular responses such as 
proliferation, differentiation and apoptosis. Currently, three major 
constituents of the MAPK family have been characterized in mammals: the 
extracellular signal-regulated kinases (ERKs) (ERK1/2, p42/p44), the c-Jun 
N-terminal kinases (JNKs) (JNK1, 2 and 3), and the p38 MAPKs consisting 
of four isoforms (α, β, γ and δ). MAPK pathways are activated either as a 
result of a series of interactions between the kinase components or through 
the formation of a signalling complex that contains multiple kinases, driven 
by a scaffold protein. c-JNKs are activated by phosphorylation of Thr and 
Tyr residues in the activation loop by mitogen-activated protein kinase kinase 
4 (MKK4) and MKK7. Interactions between proteins and scaffold proteins 
are crucial for MAPK function and regulation in the cell. For instance, kinase 
suppressor of Ras-1 (KSR) and MEK partner 1 (MP1) act as scaffold proteins 
for the ERK signalling pathway, whereas JNK-interacting proteins (JIPs) 
serve as scaffold proteins for the c-JNK pathway. Likewise, β-arrestin 2 acts 
as a scaffold protein for both the ERK and JNK signalling pathways.  
 Following activation, c-JNKs can phosphorylate multiple targets and 
have more than 50 substrates [1]. The substrates identified that are 
phosphorylated in the nucleus include some hormone receptors, as well as 
transcription factors such as the activator protein-1 (AP-1), the family of Jun 
factors (c-Jun, JunB, Jund), Elk-1, p53, the anti-activation transcription 
factor-2 (ATF-2), JDP2, c-Myc, the NAFT family, the STAT family and the 
PAX family [1]. For many of these factors, such as c-Jun, ATF-2, Elk-1 and 
p53, phosphorylation increases its activity and induces transcriptional gene 
expression [1]. Currently, the most studied substrate for JNK is c-Jun; 
however, it is not known which isoform is responsible for its 
phosphorylation. High expression of both the gene and protein of c-Jun 
precedes or coincides with periods of cell death, such as that occurring during 
embryonic development [2], after trauma [3], cerebral ischaemia [4] and 
seizures [5]. 
 c-JNKs have attracted enormous interest because their pathway has been 
linked to numerous physiological processes, including neuronal death in 
several neurodegenerative disorders such as Alzheimer’s disease and 
Parkinson’s disease. In mammals, three genes have been characterized that 
encode c-JNKs (JNK1, JNK2 and JNK3).  These proteins exhibit several 
differences in their localisation; JNK1 and JNK2 have a wide tissue 
distribution in the whole body, whereas JNK3 is primarily localized in the 
central nervous system (CNS), making it an attractive CNS drug target to 
prevent neurodegenerative diseases. In addition, JNK3 is also found in the 
heart and testis at low levels. 
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 In this chapter we reviewed the progress in understanding the role of c-
JNKs in the pathophysiology of neurodegenerative diseases and we presented 
current knowledge of JNK inhibitors in clinical trials to treat 
neurodegenerative disorders. 
 
1. Role of the JNK pathway in apoptosis: Genetically modified 
experimental models 
 
 It is impossible to study the role of c-Jun in vivo in the nervous system 
because knockout mice for c-Jun die of liver failure during embryonic 
development [6]. However, knockouts for the mammalian Jnk genes Jnk1, 
Jnk2 and Jnk3 are viable and have enabled the study of the physiological and 
pathological roles of the JNK pathway. Jnk3 (-/-) knockout mice remain 
viable during development and show normal brain structure [7]. The first 
evidence of the role of Jnk3 in neurotoxicity was provided by Yang and 
colleagues, who demonstrated that in comparison to wild-type mice, Jnk3 (-/-) 
mice were less sensitive to seizures induced by kainic acid and neuronal 
death in the hippocampal CA1 and CA3 areas. Therefore, it was concluded 
that JNK3 is a suitable target to prevent both neuronal cell death and seizures 
elicited by KA. In contrast, loss of Jnk1 or Jnk2 did not show any effects 
against KA treatment [8]. 
 Recently, we demonstrated that Jnk3 (-/-) mice had increased p110 beta 
protein levels and PI3K activity because of an upregulation of the pik3cb 
gene [9]. Accordingly, the AKT pathway was seen to be activated in Jnk3 (-/-) 
mice. However, we did not find any changes in AKT activity in Jnk1 (-/-) 
null mice. Therefore, the lack of Jnk3 selectively increases neuroprotective 
pathways, but it is unknown how the PI3K/Akt signalling pathway is 
activated in the absence of JNK3. 
 All these experimental data suggest that JNK3 is required to induce 
neuronal stress and apoptosis in adult hippocampi. The disruption of Jnk1 
or Jnk2 does not affect the nervous system, but double knockout Jnk1 (-/-) 
Jnk2 (-/-) mice die during embryonic development with major alterations 
in the neural phenotype [10,11]. This is because the neural tube fails to 
close due to a deficiency in apoptosis. However, the opposite effect has 
been observed in the developing cortex brain, where there is an increase 
in apoptosis [10,11]. This indicates that Jnk1 and Jnk2 are necessary for 
the development of cell death in the neural tube and, in turn, for 
promoting cell survival during cerebral cortex development. Thus, 
although c-JNK and c-Jun proteins are pro-apoptotic in different cell 
types, they may have other functions, as already mentioned. Furthermore, 
induction of axonal regeneration in axotomised peripheral neurons in an 
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adult organism appears to be associated with increased expression of       
c-Jun, suggesting that this transcription factor regulates the expression of 
genes related to regeneration [12].  
 Several mechanisms have been proposed to explain how the c-JNK 
pathway governs the whole process of neuronal death by apoptosis. For 
example, c-JNKs directly phosphorylate and regulate the pro- and anti-
apoptotic activity of members of the B-cell lymphoma 2 (Bcl-2) families.     
c-JNKs phosphorylate and decrease the anti-apoptotic activity of both Bcl-2 
and Bcl-XL. In addition, these kinases phosphorylate the pro-apoptotic 
protein BAD at Ser-128, thereby potentiating its pro-apoptotic effect [13]. 
Similarly, c-JNKs phosphorylate the pro-apoptotic proteins Bim and Bcl-2-
modifying factor (Bmf), causing their release and translocation to the 
mitochondria, where they promote the release of mitochondrial proteins such 
as cytochrome c, apoptosis-inducing factor (AIF) and other mitochondrial 
pro-apoptotic death mediators. An apoptotic process eventually occurs and 
could be caspase-dependent or independent.  
 As discussed, the release of cytochrome c and other pro-apoptotic 
proteins from the mitochondria is regulated by the Bcl-2 protein family.  The 
multi-domain pro-apoptotic Bcl-2 family member Bcl-2-associated X protein 
(Bax) is essential for cytochrome c release and cell death in neurons in 
response to different apoptotic stimuli. In contrast, the anti-apoptotic proteins 
Bcl-2 and Bcl-xL, which can form heterodimers with Bax, inhibit 
cytochrome c release and protect against cell death. Interestingly, several pro-
apoptotic BH3-only members are expressed in neurons and the c-JNK 
pathway could be involved in the expression of dp5, Bim and PUMA 
following an apoptotic stimulus. These BH3-only proteins may promote 
neuronal apoptosis by binding to the anti-apoptotic members of the Bcl-2 
family, which would then be unable to interact with Bax. Thus, by acting 
through both transcriptional and non-transcriptional mechanisms, c-JNKs are 
a key mediator of neuronal cell death.  
 It has been widely demonstrated that oxidative stress is involved in the 
onset of neurodegenerative disorders and favours the activation of MAPKs 
and the induction of apoptosis in a variety of experimental models [14, 15]. A 
potential link between oxidative stress and the c-JNK pathway could be by 
means of apoptosis signal regulating kinase 1 (ASK1).  Hence, it has been 
reported that treatment of embryonic fibroblasts from ASK1−/− mice with 
H2O2 does not activate JNK and the cells are resistant to oxidative stress-
induced apoptosis [16]. It has also been reported that oxidative stress induced 
by H2O2 in COS7 cells promotes the dissociation of the 14-3-3 protein from 
ASK1, which leads to the dephosphorylation of ASK1 at Ser-967, resulting in 
ASK1 and JNK activation [15, 17].  
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 Therefore, it seems that the c-JNK pathway is strongly involved in the 
process of neuronal death. This hypothesis is further supported by another 
study which showed that cdk5 activation in experimental models of 
Alzheimer's disease was associated with reactive oxygen species (ROS) 
increase and c-JNK activation.  
 Given the above, it is clear that the inhibition of c-JNKs could be a 
potent neuroprotective tool. However, suppressing the c-JNK pathway has 
limitations due to the biological functions involved. For example, it has been 
shown that c-JNK inhibitors can rescue axotomised neurons, but prevent its 
regeneration [18]. A possible alternative would be to develop direct targets 
against specific molecules of the c-JNK pathway; however, this requires 
more information about the individual actions of the different c-JNK 
isoforms. In this sense, the work of Zhao and Herdegen not only provided 
new data on the differential activity of different c-JNK isoforms, but also 
analysed mitochondria after ischaemic insult [19]. This study suggested that 
inhibiting the mitochondrial complex MKK: JNK3 attenuated apoptosis 
without affecting physiological functions.  
 Likewise, the study of Björkblom and colleagues suggests that the 
nuclear localisation of c-JNKs is the main factor responsible for cell death, 
while the cytoplasmic localization is responsible for its physiological 
functions [20]. This is an important factor to consider when designing drugs 
to treat neurodegenerative diseases. 
 
2. Control of the JNK3 pathway and neuroprotection 
 
 As we have commented above, the first evidence of the involvement of 
c-JNKs in excitotoxicity was derived from the reduction of seizures activity 
and prevention of apoptosis in JNK3-deficient mice treated with kainic acid 
[7]. In addition, mice with an inactive form of the c-jun gene (Jun AA: 
alanine instead of serine at positions 63 and 73) showed resistance to 
excitotoxic neuronal death. These data opened the study of a specific target 
to protect against neurodegenerative disorders. Thus, blocking the access of 
c-JNKs to their substrate c-Jun may offer a suitable target in 
neuroprotection [21]. 
 
2.1. Role of JNK3 and ischaemia 
 
 Pirianov et al. were the first to describe the neuroprotective role of the 
specific isoform of JNK3 in a model of hypoxic–ischaemic injury [22]. They 
demonstrated that the deletion of JNK3 had a neuroprotective role by 
reducing ATF-2 phosphorylation, which was associated with the size of the 
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infarct. Therefore, it was proposed that the JNK3/c-Jun/ATF-2 pathway was 
likely to be the main route in neural cell death induced by hypoxic–ischaemic 
injury. Moreover, the authors demonstrated that after the hypoxic–ischaemic 
injury, JNK3 activation phosphorylated c-Jun, which has been shown to 
trigger the transcription of a large number of death genes including the pro-
apoptotic Bcl-2 family member, Bim, and the death receptors TNFR (p55) 
and CD95/Fas [23, 24]. Furthermore, JNK3 signalling is implicated in the 
mitochondrial release of cytochrome c, leading to caspase-3 activation either 
via a Bim-dependent mechanism or through direct targeting of the 
mitochondria [23, 24, 25]. Jnk3 knockout in perinatal brain injury has been 
linked to a decrease in caspase-3 activity, as well as a reduction in the levels 
of the pro-apoptotic proteins PUMA and Bim.  
 The postsynaptic density protein 95 (PSD-95) is a scaffold protein 
characterized by the presence of several protein-binding domains, including 
three N-terminal PDZ domains, a signal Src homology region 3 domain and a 
C-terminal guanylate kinase-like domain. Moreover, the PDZ domains bind to 
the C-terminus of the NMDA receptor NR2 and KA receptor GluR6 subunit, 
which is crucial for the grouping of NMDA receptors and KA receptors in the 
postsynaptic membrane. It has been reported that brain ischaemia alters the 
GluR6-PSD-95-MLK3 complex in the hippocampus, which affects JNK3 
phosphorylation. Moreover, the neuroprotective role of GABA against 
ischaemic injury occurs through the inhibition of the JNK3 signalling pathway. 
 
2.2. Role of JNK3 in experimental models of Parkinson’s disease 
 
 Parkinson's disease (PD) is the second most common neurodegenerative 
disease. The mechanisms involved in its pathogenesis include oxidative stress 
production, mitochondrial dysfunction and protein aggregation, which 
promote the loss of dopaminergic neurons in the substantia nigra pars 
compacta. Currently, the main problem of PD and all neurodegenerative 
diseases is that therapy is focused on symptomatic relief. It is necessary to 
develop neuroprotective therapies that will slow disease progression. The 
investigation of cell death mechanisms common to several models of 
experimental PD may identify new drug targets for treatment.  
 It has been observed that in mice exposed to MPTP, a PD neurotoxin that 
inhibits mitochondrial complex I, dopaminergic neurons degenerate in the 
substantia nigra [26, 27]. Inhibiting c-JNKs or their upstream signals may 
reduce dopamine-mediated neuronal death induced by MPTP, suggesting a 
possible therapeutic application for c-JNK inhibitors in PD [28]. 
Pharmacological inhibition of mixed lineage kinases that are upstream of 
JNK by CEP-1347 attenuates MPTP-mediated nigrostriatal dopaminergic 
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neuronal loss and MPTP-induced c-JNK activation. Additionally, 
dopaminergic neuronal death induced by MPTP, rotenone, paraquat and 6-
hydroxydopamine all require JNK3 activation. Therefore, JNK3 is a critical and 
common mediator of dopaminergic neuronal death in PD experimental models.  
 Hunot and colleagues demonstrated that mice treated with MPTP showed 
increased COX-2 expression that was mediated by JNK [29]. Interestingly, 
COX-2 expression is upregulated in PD brains and is generally induced by 
stress stimuli. Moreover, COX-2 localizes in neurons and its expression is 
upregulated in numerous pathological conditions, including Alzheimer's 
disease. Therefore, COX-2 induction might represent an important step in the 
cascade of molecular events leading to PD neurodegeneration.   
 Disappointingly, a clinical trial using CEP1347 to treat PD was 
terminated because it failed to produce significant improvements. The main 
problem of this compound is its poor selectivity against JNK3, the main 
target involved in apoptosis. As we previously discussed, JNK1 and 2 are 
ubiquitously expressed in adult tissues and have important physiological 
functions; hence, the side effects associated with inhibiting these enzymes 
limit the tolerable doses of JNK inhibitors. Accordingly, general inhibition of 
all JNK isoforms, such as that achieved by CEP1347, may be of limited 
benefit to treat neurodegenerative diseases. On the other hand, JNK3 is 
neural-specific and does not exhibit high basal activity in the brain. 
Therefore, selective or specific inhibition of the JNK3 isoform may be more 
specific to slow down PD progression. 
 
2.3. Role of JNK3 in Alzheimer’s disease 
 
 Alzheimer's disease (AD) is currently the leading global cause of 
dementia in the elderly. At the initial stages, AD is characterised by a mild 
loss of memory and then progresses to a severe loss of cognitive performance 
in the advanced stages [30]. From histological images, AD is characterised by 
a series of markers that include neurofibrillary tangles, senile plaques and a 
large loss of neurons. Apart from these markers, the loss of neurons is 
associated with apoptosis, which is probably mediated by several inducers 
such as reactive oxygen species, β-amyloid, mitochondrial alteration and an 
inflammatory process that induces microglial activation in the AD brain. In 
this process of neuronal demise in AD, different signalling pathways are 
activated and among them, the JNK pathway plays a prominent role. This is 
based on several lines of evidence: (a) JNK can phosphorylate tau; (b) β-
amyloid activates the JNK pathway that then promotes neuronal loss and this 
activation mediates Aβ toxicity and its adverse effect on long-term potential in 
the hippocampus and (c) JNK translocates from the nucleus to the cytoplasm 
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following the course of disease severity [31], and its upstream activator, 
MEK1, is also activated in vulnerable neurons in AD [32]. Furthermore, it has 
been previously reported that expression of c-Jun increases in the AD brain and 
neurons from c-Jun-null mice are resistant to β-amyloid toxicity [33]. A recent 
study reported that c-Jun is specifically phosphorylated at Ser63 in AD, 
whereas c-Jun phosphorylation at Ser73 does not change, suggesting it is 
differential phosphorylation that underlies cell death in AD [34].   
 Morishima et al. were the first to demonstrate that neuronal hippocampal 
and cortical cultures of JNK3 knockout mice were partially protected from 
neuronal apoptosis mediated by β-amyloid [35]. However, c-Jun 
phosphorylation was not completely inhibited, indicating that JNK1 or JNK2 
may be involved in this phosphorylation [35]. On the other hand, a very 
important point in AD is the formation of β-amyloid fragments that are 
derived from amyloid precursor protein (APP) after cleavage by beta/gamma 
secretase. The C-terminal intracellular region (AICD) of APP plays an 
important functional role in regulating APP metabolism. AICD contains eight 
potential phosphorylation sites, but one of them, specifically T668, is 
phosphorylated by several kinases including GSK3β, JNK3, Cdc2 and Cdk5. 
Likewise, these kinases are associated with neurotoxicity and have been 
implicated in neurodegenerative diseases. Interestingly, JNK3 is specifically 
involved in the physiological regulation of AICD during neuronal 
differentiation, suggesting a role of JNK3 in synaptogenesis [36].   
 Moreover, Colombo and colleagues used the JNK inhibitor peptide (D-
JNKI1) to demonstrate that JNK plays a prominent role in APP production 
and that the extracellular β-amyloid fragments are also reduced [37]. It has 
been observed that β-secretase (BACE1) is regulated by BACE1 gene 
transcription through the JNK/c-Jun signalling pathway. This is important 
because it has been hypothesized that β-amyloid fragments are mainly 
responsible for the neurodegeneration in AD.  
 Studies performed in neuronal cell cultures have shown that JNK3 is 
involved in the apoptotic process mediated by β- amyloid. This process involves 
MLK3–MKK7–JNK3 activation, as well as downstream events including p-JNK 
nuclear localization, c-Jun phosphorylation and Bad translocation to the 
mitochondria, with the mitochondria then releasing pro-apoptotic proteins. 
 
2.4. JNK and Huntington’s disease 
 
 Huntington’s disease (HD) is a progressive neurodegenerative disorder 
caused by an autosomal dominant mutation in either of the two copies of the 
huntingtin gene. Specifically, this disorder is caused by an abnormal 
expansion of a CAG codon in exon-1 of the gene [38].  
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 Systemic administration of mitochondrial toxin 3-nitropropionic acid (3-
NPA) to experimental animals, such as non-human primates and rodents, 
produces symptoms similar to those of human HD. Thus, 3-NPA is used in 
the laboratory to replicate neurodegenerative conditions [39]. The toxin 
irreversibly inhibits the succinate dehydrogenase (SDH) enzyme, the main 
constituent of the mitochondrial respiratory chain complex (MCC) II [40].  
 Treatment of rats and in vitro primary striatal cultures with 3-NPA 
activates the JNK pathway and contributes to neuronal death [41]. This cell 
loss depends on c-Jun because expression of dominant negative c-Jun 
protects striatal neurons from cell death mediated by this complex II 
inhibitor. Likewise, JNK activation appears to be a major factor in the 
apoptotic death of HN33 cells induced by polyglutamine-expanded 
huntingtin. Mutated huntingtin with 48 or 89 polyglutamine repeats enhances 
JNK activation and may trigger apoptosis, while normal huntingtin with 16 
repeats fails to activate the JNK pathway.  
 However, a recent study demonstrated that the intraperitoneal 
administration of 3-NPA to Jnk3 (-/-) mice was not neuroprotective in contrast 
to the neurotoxin KA [42]. This suggests that although the JNK pathway may 
be activated in this model, JNK3 is probably not mainly responsible for 
neuronal death and other pathways may be involved in neuronal loss.  
 
3. Neuroprotective effects of JNK inhibitors 
 
 As already discussed, since the activation of the c-JNK pathway may be 
a common step in various neurodegenerative diseases, the pharmacological 
inhibition of JNK is a suitable strategy to protect against neuronal death. In 
this sense, we highlight three chemical inhibitors: CEP-1347, an inhibitor of 
the MLK family of the JNK pathway, and SP600125 and AS601245, both 
selective inhibitors of JNK activity. 
 
                    
                        
 
                            CEP-1347                                          SP600125 
 
Figure 1. Molecular structures of the c-JNK inhibitors CEP-1347 and SP600125. 
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 The main limitation of the CEP-1347 inhibitor is its poor selectivity 
because it acts upstream of JNK activators, namely the MLKs [43].  This 
compound has shown neuroprotective effects both in vitro and in vivo against 
β-amyloid toxicity, trophic withdrawal in PC12 cells, MPP+ exposure and 
apoptosis in cerebellar granule cells following serum and potassium 
deprivation. Moreover, in addition to inhibiting the pro-apoptotic JNK 
pathway, this drug activates neurotrophic pathways, including the 
neurotrophin BDNF in a mouse model of HD. Specifically, CEP-1347 
increases BDNF mRNA levels in the brain compared to vehicle, which 
correlates with a reduction of disease progression in a pilot pre-clinical trial 
in R6/2 mice, an experimental model of HD. 
 However, although the PRECEPT clinical trial showed that CEP-1347 
was safe and well-tolerated in a randomised placebo-controlled study in PD 
subjects, it was concluded that this drug was not effective to treat PD. 
Nevertheless, further studies are needed to assess why this drug was not 
effective.  
 SP600125 is a reversible ATP-competitive inhibitor that can inhibit JNK, 
including JNK-1, -2 and -3 isoforms, with high selectivity. The 
neuroprotective effect of SP600125 has been seen in ischaemic processes 
[44]. Other studies have further demonstrated that SP600125 can inhibit the 
phosphorylation of c-Jun and prevent the expression of IL-2, IFN-γ, TNF-α 
and COX-2, while inactivating Bcl-2 and blocking IL-1-induced 
accumulation of p-Jun and inducing c-Jun transcription [44, 45, 46, 47]. 
 SP600125 exerts neuroprotective effects against MPTP-induced 
neurotoxicity in mice, inhibiting JNK signalling and also reducing COX-2 
expression [48]. Moreover, SP600125 displays neuroprotective functions in 
β-amyloid-injected rats, as it has potent memory-enhancing effects and 
blocks learning deficits induced by β-amyloid [49]. In addition to the 
neuroprotective properties of SP600125, this compound also improves 
neuroplasticity. Effectively, this JNK inhibitor increases synaptic 
transmission in the hippocampus after treatment with β-amyloid in the CA1 
area, suggesting a role of JNK in regulating short-term memory formation. 
More studies are required to evaluate the effects of SP600125 in β-amyloid 
production in AD models; however, its low water solubility limits its 
usefulness in human treatment.  
 AS601245 is also a reversible ATP-competitive inhibitor that inhibits the 
three JNK isoforms, with a higher affinity for JNK3. This compound exhibits 
neuroprotective effects in models of ischaemia [50]. It also decreases 
microglial activation and exerts beneficial effects on memory deficits.  
 As mentioned above, JNK activity can be regulated by JNK-interacting 
proteins. JIP-1 is a protein that integrates the positive and negative regulators 
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of JNK, facilitating the activity of the JNK signalling pathway. In mice, JIP-1 
contains a JNK-binding domain (JBD) that mediates the sequestration of JNK 
in the cytoplasm, thus inhibiting the expression of genes that are activated via 
the JNK signalling pathway and acts as a functional inhibitor of JNK. 
Therefore, in addition to chemical inhibitors, JIP-derived peptides have been 
developed to inhibit JNK activity based on the properties of the protein JIP-1. 
The most studied peptide is XG-102, also called D-JNK-permeable peptide 1 
(D-JNKI). It exerts neuroprotective effects against different models of 
excitotoxicity in vitro and has also been shown to play a neuroprotective role 
in experimental models of ischaemia, preventing cell death by apoptosis. 
 Thus, rather than inhibiting the enzymatic activity of JNKs as classical 
chemical inhibitors do, XG-102 selectively blocks the access of JNK to 
different substrates, preventing protein-protein interactions without 
interfering with its activation. Moreover, XG-102 has been observed to show 
beneficial effects on both hair cell death and the permanent loss of hearing 
induced by sound trauma [51]. A phase I/II clinical study with XG-102 is 
currently underway to evaluate the efficacy of this compound in patients with 
acute acoustic trauma; the study will be completed in 2012. Therefore, in the 
coming years, more clinical data will shed light on the neuroprotective 
potential of these compounds. 
 
4. Future perspectives of inhibiting the JNK pathway in the 
treatment of neurodegenerative diseases  
 
 The increase in life span is expected to see an increase in 
neurodegenerative diseases, with the most important being Alzheimer’s 
disease. The development of neuroprotective drugs is undoubtedly an area of 
increasing relevance due to the high incidence and prevalence of 
neurodegenerative diseases and the lack of effective treatments. However, 
since the exact mechanism of neuronal cell death in neurodegenerative 
diseases is not known, this limits the success in searching for effective drugs. 
Given that the process of neuronal death is complex, to at least find a drug 
that effectively blocks a pathway involved in cell death or delays the progress 
of AD, PD or HD is considered a success. Apart from c-JNK activation in 
neurodegenerative diseases, other biochemical parameters such as oxidative 
stress, mitochondrial alteration, cell cycle re-entry, cytoskeletal alteration, an 
increase in GSK-3 activation and inhibition of pro-survival pathways (such as 
the AKT pathway) might also contribute to the neurodegenerative process. 
Therefore, targeting the c-JNK pathway with effective inhibitors at least 
provides a powerful way to experimentally achieve neuroprotection, as well 
as preserving cognitive function, inhibiting apoptosis and having a trophic 
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function. Unfortunately, clinical studies with CEP-1347 in PD have failed, but 
the loss of drug efficacy could have been due to multiple causes, such as 
whether the clinical trial (selected patients) for the specific compound was well 
designed or not. Other possible causes could have been a failure of the dose, 
administering the drug when the neurons were already dead, or the drug 
rescuing non-functioning neurons that could not perform their physiological 
roles. Therefore, it is necessary to conduct more clinical studies with inhibitors 
of the c-JNK pathway. It would probably be interesting to consider clinical 
trials with two drugs, such as an antioxidant, a GSK3β inhibitor or other c-JNK 
antagonists, since more than one pathway may be involved in neuronal death 
and this might be more effective in treating neurodegenerative diseases. 
 
Acknowledgements 
 
 We thank the Language Advisory Service of the University of Barcelona 
for revising the manuscript. This study was supported by the grants SAF-
2009-13093 and BFU2010-19119/BFI from the Ministerio de Educación y 
Ciencia, PI080400 from the Instituto de Salud Carlos III, 2009/SGR00853 
from the Generalitat de Catalunya and grant 610RT0405 from the Programa 
Iberoamericano de Ciencia y Tecnologia para el Desarrollo (CYTED). 
 
References 
 
1. Bogoyevitch, MA., Kobe, B. 2006, Microbiol. Mol. Biol. Rev., 70(4), 1061. 
2. Sun, W., Gould, TW., Newbern, J., Milligan, C., Choi, SY., Kim, H., 
 Oppenheim, RW. 2005, J. Neurosci., 25(23), 5595. 
3. Raivich, G., Bohatschek, M., Da Costa, C., Iwata, O., Galiano, M., Hristova, M., 
 Nateri, AS., Makwana, M., Riera-Sans, L., Wolfer, DP., Lipp, HP., Aguzzi, A., 
 Wagner, EF., Behrens, A. 2004, Neuron, 43(1), 57. 
4. Wessel, TC., Joh, TH., Volpe, BT. 1991, Brain Res., 567(2), 231. 
5. Morgan, JI., Curran, T. 1988, Cell Calcium, 9(5-6), 303. 
6. Hilberg, F., Aguzzi, A., Howells, N., Wagner, EF. 1993, Nature, 365(6442), 179. 
7. Yang, DD., Kuan, CY., Whitmarsh, AJ., Rincón, M., Zheng, TS., Davis, RJ.,
 Rakic, P., Flavell, RA. 1997, Nature, 389(6653), 865. 
8. Brecht, S., Kirchhof, R., Chromik, A., Willesen, M., Nicolaus, T., Raivich, G., 
 Wessig, J., Waetzig, V., Goetz, M., Claussen, M., Pearse, D., Kuan, CY., 
 Vaudano, E., Behrens, A., Wagner, E., Flavell, RA., Davis, RJ., Herdegen, T. 
 2005, Eur. J. Neurosci., 21(2), 363. 
9. Junyent, F., de Lemos, L., Verdaguer, E., Folch, J., Ferrer, I., Ortuño-Sahagún, 
 D., Beas-Zárate, C., Romero, R., Pallàs, M., Auladell, C., Camins, A. 2011, J. 
 Neurochem., 117(2), 244. 
10. Kuan, CY., Yand, DD., Samanta Roy, DR., Davis, RJ., Rakic, P., Flavell, RA. 
 1999, Neuron, 22(4), 667. 
JNK and neurodegeneration  27 
11. Sabapathy, K., Jochum, W., Hochedlinger, K., Chang, L., Karin, M., Wagner, 
 EF. 1999, Mech. Dev., 89(1-2), 115. 
12. Herdegen, T., Skene, P., Bähr, M. 1997, Trends Neurosci., 20(5), 227. 
13. Donovan, N., Becker, EB., Konishi, Y., Bonni, A. 2002, J. Biol. Chem., 277(43), 
 40944. 
14. Bhat, NR., Zhang, P. 1999, J. Neurochem., 72(1), 112. 
15. Goldman, EH., Chen, L., Fu, H. 2004, J. Biol. Chem., 279(11), 10442. 
16. Tobiume, K., Matsuzawa, A., Takahashi, T., Nishitoh, H., Morita, K., Takeda, 
 K., Minowa, O., Miyazono, K., Noda, T., Ichijo, H. 2001, EMBO Rep., 2(3), 222. 
17. Zhang, L., Chen, J., Fu, H. 1999, Proc. Natl. Acad. Sci. USA., 96(15), 8511. 
18. Newbern, J., Taylor, A., Robinson, M., Lively, MO., Milligan, CE. 2007, 
 Neuroscience, 147(3), 680. 
19. Zhao, Y., Herdegen, T. 2009, Mol. Cell. Neurosci., 41(2), 186. 
20. Björklom, B., Vainio, JC., Hongisto, V., Herdegen, T., Courtney, MJ., Coffey, 
 ET. 2008, J. Biol. Chem., 283(28), 19704. 
21. Behrens, A., Sibilla, M., Wagner, EF. 1999, Nat. Genet., 21(3), 326. 
22. Pirianov, G., Brywe, KG., Mallard, C., Edwards, AD., Flavell, RA., Hagberg, 
 H.,Mehmet, H. 2007, J. Cereb. Blood Flow Metab., 27(5), 1022. 
23. Whitfield, J., Neame, SJ., Paquet, L., Bernard, O., Ham, J. 2001, Neuron, 29(3), 629. 
24. Kuan, CY., Whitmarsh, AJ., Yang, DD., Liao, G., Schloemer, AJ., Dong, C., 
 Bao, J., Banasiak, KJ., Haddad, GG., Flavell, RA., Davis, DJ., Rakic, P. 2003, 
 Proc. Natl. Acad. Sci. USA, 100(25), 15184. 
25. Borsello, T., Clarke, PG., Hirt, L., Vercelli, A., Repici, M., Schorderet, DF., 
 Bogousslavsky, J., Bonny, C. 2003, Nat. Med., 9(9), 1180. 
26. Oo, TF., Henchcliffe, C., James, D., Burke, RE. 1999, J. Neurochem., 72(2), 557. 
27. Saporito, MS., Hudkins, RL., Maroney, AC. 2002, Prog. Med. Chem., 40, 23. 
28. Borsello, T., Forloni, G. 2007, Curr. Pharm. Des., 13(18), 1875. 
29. Hunot, S., Vila, M., Teismann, P., Davis, RJ., Hirsch, EC., Przedborski, S., 
 Rakic, P., Flavell, RA. 2004, Proc. Natl. Acad. Sci. USA., 101(2), 665. 
30. Smith, MA. 1998, Int. Rev. Neurobiol., 42, 1. 
31. Zhu, X., Raina, AK., Rottkamp, CA., Aliev, G., Perry, G., Boux, H., Smith, MA. 
 2001, J. Neurochem., 76, 435. 
32. Zhu, X., Sun, X., Lee, HG., Siedlak, SL., Perry, G., Smith, MA. 2003, J. 
 Neurochem., 86(1), 136. 
33. Anderson, AJ., Su, JH., Cotman, CW. 1996, J. Neurosci., 16(5), 1710. 
34. Pearson, AG., Byrne, UT., MacGibbon, GA., Faull, RL., Dragunow, M. 2006, 
 Neurosci. Lett., 398(3), 246. 
35. Morishima, Y., Gotoh, Y., Zieg, J., Barrett, T., Takano, H., Flavell, R., Davis, 
 RJ., Shirasaki, Y., Greenberg, ME. 2001, J. Neurosci., 21(19), 7551. 
36. Kimberly, WT., Zheng, JB., Town, T., Flavell, RA., Selkoe, DJ. 2005, J. 
 Neurosci., 25(23), 5533. 
37. Colombo, A., Bastone, A., Ploia, C., Sclip, A., Salmona, M., Forloni, G., 
 Borsello, T. 2009, Neurobiol. Dis., 33(3), 518. 
38. No authors listed. 1993, Cell, 72, 971. 
39. Brouillet, E., Jacquard, C., Bizat, N., Blum, D. 2005, J. Neurochem., 95(6), 1521. 
Fèlix Junyent et al. 28
40. Brouillet, E., Guyot, MC., Mittoux, V., Altairac, S., Condé, F., Palfi, S., 
 Hantraye, P. 1998, J. Neurochem., 70(2), 794. 
41. Garcia, M., Vanhoutte, P., Pages, C., Besson, MJ., Brouillet, E., Caboche, J. 
 2002, J. Neurosci., 22(6), 2174794. 
42. Junyent, F., de Lemos, L., Verdaguer, E., Pallàs, M., Folch, J., Beas-Zárate, C., 
 Camins, A., Auladell, C. 2011, Neuropathol. Appl. Neurobiol., doi: 
 10.1111/j.1365-2990.2011.01214.x. 
43. Saporito, MS., Hudkins, RL., Maroney, AC. 2002, Prog. Med. Chem., 40, 23. 
44. Guan, QH., Pei, DS., Zhang, QG., Hao, ZB., Xu, TL., Zhang, GY. 2005, Brain 
 Res., 1035, 51. 
45. Bennett, BL., Sasaki, DT., Murray, BW., O’Leary, EC., Sakata, ST., Xu, W., 
 Leisten, JC., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, SS., Manning, AM., 
 Anderson, DW. 2001, Proc. Natl. Acad. Sci. USA., 98(24), 13681. 
46. Shin, M., Yan, C., Boyd, D. 2002, Biochim. Biophys. Acta, 1589(3), 311. 
47. Han, Z., Boyle, DL., Chang, L., Bennett, B., Karin, M., Yang, L., Manning, AM., 
 Firestein, GS. 2001, J. Clin. Invest., 108(1), 73. 
48. Whang, Y., Zhang, Y., Wei, Z., Li, H., Zhou, H., Zhang, Z., Zhang, Z. 2009, J. 
 Neurol. Sci., 285(1-2), 172. 
49. Ramin, M., Azizi, P., Motamedi, F., Haghparast, A., Khodagholi, F. 2011, Behav. 
 Brain Res., 217(2), 424. 
50. Carboni, S., Hiver, A., Szyndralewiez, C., Gaillard, P., Gotteland, JP., Vitte, PA. 
 2004, J. Pharmacol. Exp. Ther., 310(1), 25. 
51. Whang, J., Ruel, J., Ladrech, S., Bonny, C., van de Water, TR., Puel, JL. 2007, 
 Mol. Pharmacol., 71, 654. 
 
 
 
 
